Minerva Neurosciences, Inc. (NERV)
NCM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Minerva Neurosciences Annual Report Highlights Cash Runway and Clinical Pipeline
# 🧾 What This Document Is This is Minerva Neurosciences' Annual Report to Shareholders (ARS). Think of it as the company's comprehensive "year in review" document, sent to all its owners (shareholders). It goes beyond the basic financial numbers to explain the business strategy, highlight major ac
Minerva Neurosciences, Inc. — 8-K Filing
# 🧾 What This Document Is This is a **Form 8-K filing**, which companies use to announce major events to investors. This particular filing has three attached exhibits that together tell one complete story: the departure of Minerva's President, Geoff Race, and the hiring of his replacement. The docu
SEC filings
All filings →Insider trades
All insider trades →Minerva Neurosciences, Inc. has no reported insider trades in the last 90 days.